Structure Therapeutics(GPCR) - 2024 Q4 - Annual Results

Exhibit 99.1 Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in- human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term invest ...